AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26194955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (HL and AF)
Number of subjects: 86
Study 23350886 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nursing visits (two interviews: one day before surgery and one just before entering the operating room)
Number of subjects: 100
Study 23350886 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nursing visits
Number of subjects: 100
Study 23350886 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 100
Study 20978525 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine supplementation (4 g/day)
Number of subjects: 63
Study 20978525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mineral water 500 ml/day without betaine)
Number of subjects: 63
Study 20158691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg every 3 months intravenously for 1 year, along with calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Number of subjects: 74
Study 20158691 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Number of subjects: 74
Study 17098464 — intervention group
Group type: EXPERIMENTAL
Intervention: galyfilcon A (silicone hydrogel)
Number of subjects: 24
Study 17098464 — intervention group
Group type: COMPARATOR
Intervention: alphafilcon A (conventional hydrogel)
Number of subjects: 24
Study 16331019 — intervention group
Group type: EXPERIMENTAL
Intervention: Arc-deposited hydroxyapatite-coated cup with alumina-on-alumina bearing surface
Number of subjects: 0
Study 16331019 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous-coated cup with alumina-on-alumina bearing surface
Number of subjects: 0
Study 16331019 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous-coated cup with polyethylene-on-metal bearing surface
Number of subjects: 0
Study 16331019 — intervention group
Group type: COMPARATOR
Intervention: Grit-blasted hydroxyapatite-coated cup with polyethylene-on-metal bearing surface
Number of subjects: 0
Study 11932878 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado/Soybean Unsaponifiables (ASU)
Number of subjects: 163
Study 11932878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 9797114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube tissue specimens from infertile women with chronic salpingitis and/or salpingitis isthmica nodosa
Number of subjects: 56
Study 9797114 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 fertile women)
Number of subjects: 56
Study 8600589 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(4,5) PFUs per dose
Number of subjects: 200
Study 8600589 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,1) PFUs per dose
Number of subjects: 200
Study 8600589 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,9) PFUs per dose
Number of subjects: 200
Study 8600589 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(2,7) PFUs per dose
Number of subjects: 200
Study 8600589 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka strain)
Number of subjects: 200
Study 2529543 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (oral administration)
Number of subjects: 8
Study 2529543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 361345 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine (average maximum daily dose: 60.0 mg)
Number of subjects: 47
Study 361345 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (average daily dosage: 36.8 mg)
Number of subjects: 47
Study 361345 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine (average daily dosage: 81.1 mg)
Number of subjects: 47
Study 361345 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (average daily dosage: 90.1 mg)
Number of subjects: 47
Study 31257404 — intervention group
Group type: EXPERIMENTAL
Intervention: α1 microglobulin (α1m)
Number of subjects: 2377
Study 31257404 — intervention group
Group type: EXPERIMENTAL
Intervention: β2 microglobulin (β2m)
Number of subjects: 2377
Study 31257404 — intervention group
Group type: EXPERIMENTAL
Intervention: Uromodulin
Number of subjects: 2377
Study 27995369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesics (paracetamol, ibuprofen, or a combination)
Number of subjects: 884
Study 27995369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodily Pain Score of the SF-36
Number of subjects: 884
Study 25796191 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density genetic map construction using 1712 SSR primer pairs
Number of subjects: 0
Study 25796191 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological markers identified
Number of subjects: 0
Study 23786776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/week
Number of subjects: 125
Study 23786776 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 125
Study 23786776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 21698928 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized surgical tactics
Number of subjects: 210
Study 21698928 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical approaches
Number of subjects: 210
Study 19175639 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma (DS)
Number of subjects: 4417
Study 19175639 — intervention group
Group type: COMPARATOR
Intervention: No defunctioning stoma (without DS)
Number of subjects: 4417
Study 17034438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention support group
Number of subjects: 291
Study 17034438 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized brief motivational enhancement
Number of subjects: 291
Study 17034438 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 291
Study 15222971 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants with no interruption
Number of subjects: 101
Study 15222971 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants interrupted early
Number of subjects: 101
Study 15222971 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants interrupted late
Number of subjects: 101
Study 15222971 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants interrupted both early and late
Number of subjects: 101
Study 15222971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysexecutive patients
Number of subjects: 101
Study 15222971 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-matched controls
Number of subjects: 101
Study 11206598 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly fluoxetine
Number of subjects: 109
Study 11206598 — intervention group
Group type: COMPARATOR
Intervention: Once-daily fluoxetine
Number of subjects: 109
Study 9493921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory polysomnographic (LPSG) monitoring
Number of subjects: 64
Study 9493921 — intervention group
Group type: EXPERIMENTAL
Intervention: Home polysomnographic (HPSG) monitoring
Number of subjects: 64
Study 7691017 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 35
Study 7691017 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 35
Study 7691017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 35
Study 3705820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranquilizers, antidepressants, neuroleptics, nootropic drugs, and rational psychotherapy
Number of subjects: 138
Study 3705820 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental and psychological examination
Number of subjects: 138
Study 3705820 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up
Number of subjects: 138
Study 3705820 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided tomography
Number of subjects: 138
Study 3705820 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalo-, rheoencephalo- and echoencephalography
Number of subjects: 138
Study 30524424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) for peanut allergy
Number of subjects: 21
Study 27367877 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month intervention (n=148) including PCP and patient training, case management by trained nurses, and clinical decision support for PCPs.
Number of subjects: 291
Study 27367877 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=143) provided by primary care physician including periodic contacts, referrals to specialists, and prescription of medication.
Number of subjects: 291
Study 24381088 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) cuff inflated during the first 75 s of recovery period to prolong muscle ischemia
Number of subjects: 16
Study 24381088 — intervention group
Group type: COMPARATOR
Intervention: No intervention (baseline measures)
Number of subjects: 16
Study 22005648 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived CD3(+) cell count (ddCD3) <110/μL at 8 weeks post-transplantation
Number of subjects: 0
Study 22005648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ddCD3 at 8 weeks post-transplantation
Number of subjects: 0
Study 22005648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ddCD3 when partially chimeric
Number of subjects: 0
Study 20881958 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine
Number of subjects: 577
Study 20881958 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 577
Study 18541128 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation: ibuprofen (400 mg capsule)
Number of subjects: 24
Study 15908741 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 100
Study 15908741 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 12135217 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion hysterosonography
Number of subjects: 117
Study 12135217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 117
Study 12135217 — intervention group
Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 117
Study 10374704 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus aspirin (single therapy)
Number of subjects: 19
Study 10374704 — intervention group
Group type: COMPARATOR
Intervention: Complete therapy (lymphocyte immunizations, heparin, and aspirin)
Number of subjects: 19
Study 7487614 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pars plana vitrectomy (VIT)
Number of subjects: 420
Study 7487614 — intervention group
Group type: COMPARATOR
Intervention: Vitreous tap or biopsy (TAP)
Number of subjects: 420
Study 7487614 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (ceftazidime and amikacin)
Number of subjects: 420
Study 7487614 — intervention group
Group type: EXPERIMENTAL
Intervention: No systemic antibiotics
Number of subjects: 420
Study 2299370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LD ARA‐C) 20 mg/m2 for 21 days
Number of subjects: 87
Study 2299370 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (rubidazone 100 mg/m2 for 4 days, ARA‐C 200 mg/m2 for 7 days)
Number of subjects: 87
Study 6788069 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eyedrops, 4 times a day
Number of subjects: 17
Study 6788069 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium cromoglycate eyedrops
Number of subjects: 17
Study 29159870 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive hyperglycemia and hypoglycemia minimization (PHHM) system
Number of subjects: 28
Study 29159870 — intervention group
Group type: COMPARATOR
Intervention: Predictive low glucose suspension (PLGS) alone
Number of subjects: 28
Study 26619790 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with 6 g inulin (YI)
Number of subjects: 19
Study 26619790 — intervention group
Group type: COMPARATOR
Intervention: Yogurt without inulin (YC)
Number of subjects: 19
Study 25366680 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with concomitant boost (AFX-C)
Number of subjects: 721
Study 25366680 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (SFX)
Number of subjects: 721
Study 25366680 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive patients
Number of subjects: 721
Study 25366680 — intervention group
Group type: COMPARATOR
Intervention: p16-negative patients
Number of subjects: 721
Study 23106890 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg daily
Number of subjects: 545
Study 23106890 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg daily
Number of subjects: 545
Study 20335449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (home-based stationary cycling program from 20 wk gestation to delivery)
Number of subjects: 84
Study 20335449 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 84
Study 18586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 60
Study 18586132 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice
Number of subjects: 60
Study 18586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 60
Study 15941825 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 89
Study 15941825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal prong
Number of subjects: 89
Study 15941825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal device used (mask or prong)
Number of subjects: 89
Study 11836166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis at diagnosis
Number of subjects: 130
Study 11836166 — intervention group
Group type: EXPERIMENTAL
Intervention: t(9;22) chromosomal rearrangement
Number of subjects: 130
Study 11836166 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow response to therapy (assessed by percentage of blast cells higher than 10% in bone marrow study on day 14)
Number of subjects: 130
Study 11836166 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow response to therapy (assessed by presence of blast cells in peripheral blood on day 8)
Number of subjects: 130
Study 11836166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic study results
Number of subjects: 130
Study 10480703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to any individual allergens tested
Number of subjects: 1816
Study 10480703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 1816
Study 10480703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy in symptomatic individuals
Number of subjects: 1816
Study 8707777 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic children (n=36)
Number of subjects: 92
Study 8707777 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=36)
Number of subjects: 92
Study 8707777 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic children (n=10)
Number of subjects: 92
Study 8707777 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=10)
Number of subjects: 92
Study 1986564 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, titrated to reduce mean arterial pressure by 10 mm Hg
Number of subjects: 12
Study 1986564 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric 0.8 g/kg protein diet
Number of subjects: 12
Study 6406156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimotapp
Number of subjects: 24
Study 6406156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 24
Study 6406156 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 31126281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing real-life longitudinal study of difficult asthma
Number of subjects: 0
Study 29878445 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training once-a-week for 9 months
Number of subjects: 106
Study 29878445 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training twice-a-week for 9 months
Number of subjects: 106
Study 29878445 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training three-times-a-week for 9 months
Number of subjects: 106
Study 29878445 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group
Number of subjects: 106
Study 29878445 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 106
Study 27498129 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-T plus pertuzumab
Number of subjects: 110
Study 27498129 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC plus pertuzumab
Number of subjects: 110
Study 25997778 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (2 × 10‐15 repetitions at 80% of 1RM)
Number of subjects: 56
Study 25997778 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (1 × 80‐100 repetitions at 20% of 1RM)
Number of subjects: 56
Study 25997778 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW+ (1 × 60 repetitions at 20% of 1RM + 1 × 10‐20 repetitions at 40% 1RM)
Number of subjects: 56
Study 22669350 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vision lenses
Number of subjects: 92
Study 20887414 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 41
Study 20887414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 18541827 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/d)
Number of subjects: 371
Study 16000281 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FCWAY (5‐HT 1A receptor antagonist)
Number of subjects: 22
Study 16000281 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory Scale
Number of subjects: 22
Study 12413702 — intervention group
Group type: EXPERIMENTAL
Intervention: Qatoor Ramad (QR) eye drops, 2 drops (3-4 times/day) for up to 14 days
Number of subjects: 70
Study 12413702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 70
Study 10621951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg orally)
Number of subjects: 14
Study 10621951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10621951 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treatment with serotonin specific reuptake inhibitors (SSRIs)
Number of subjects: 14
Study 7860745 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol with high saturated fat
Number of subjects: 84
Study 7860745 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol with increased polyunsaturated fat
Number of subjects: 84
Study 7860745 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d cholesterol with high saturated fat
Number of subjects: 84
Study 7860745 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d cholesterol with low saturated fat
Number of subjects: 84
Study 7860745 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol with low saturated fat
Number of subjects: 84
Study 1955161 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection (1:10,000)
Number of subjects: 42
Study 1955161 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection + Nd:YAG laser photocoagulation
Number of subjects: 42
Study 6135908 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118630 (100 micrograms daily)
Number of subjects: 8
Study 6135908 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118630 (250 micrograms daily)
Number of subjects: 8
Study 30811282 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide and Leuprolide with Abiraterone and Prednisone (ELAP)
Number of subjects: 75
Study 30811282 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide and Leuprolide (EL)
Number of subjects: 75
Study 30811282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ELAP and EL
Number of subjects: 75
Study 28672094 — intervention group
Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 81
Study 28672094 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 81
Study 27548711 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Diet (ED)
Number of subjects: 17
Study 24393134 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 125 μg QD
Number of subjects: 163
Study 24393134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 24393134 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 163
Study 24393134 — intervention group
Group type: COMPARATOR
Intervention: Other UMEC doses (15.6, 31.25, 62.5 μg)
Number of subjects: 163
Study 21978210 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily aphasia therapy
Number of subjects: 59
Study 21978210 — intervention group
Group type: COMPARATOR
Intervention: Usual care therapy
Number of subjects: 59
Study 19131432 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV via a conventional ventilator
Number of subjects: 16
Study 19131432 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP via a variable flow device
Number of subjects: 16
Study 19131432 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV via a variable flow device
Number of subjects: 16
Study 19131432 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP via a constant flow underwater bubble system
Number of subjects: 16
Study 17457705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol as PCA with an infusion of 0.3 mg/kg following a loading dose of 1.5 mg/kg administered 1 hour before the end of the surgery
Number of subjects: 120
Study 17457705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg/kg following induction of anesthesia
Number of subjects: 120
Study 17457705 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine as PCA with an infusion following a loading dose of 0.15 mg/kg administered 30 minutes before the end of surgery
Number of subjects: 120